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ABSTRACT

Background: Clinical breakpoints and epidemiological cut-off values for N. gonorrhoeae azithromycin
antimicrobial susceptibility testing have not been established. This study utilized existing minimum
inhibitory concentration (MIC) data from CDC’s Gonococcal Isolate Surveillance Project (GISP) to
establish epidemiological cut-off values for azithromycin and N. gonorrhoeae as determined by agar
dilution.
Methods: MIC distributions for the pooled dataset and each data year (2005-2012) were constructed.
Epidemiological cut-off values were calculated using two methods. Method 1 considers the wild-type
MIC distribution, the modal MIC for the distribution, and the inherent variability of the test (±1 twofolddilution). Method 2 defines the epidemiological cut-off value as two twofold-dilutions higher than the
MIC50.
Results: Taking into consideration the wild-type MIC distributions and the inherent variability of the
test, the epidemiological cut-off value chosen for the pooled dataset and each data year using Method 1
was ≤1.0 µg/mL. The MIC50 for the pooled dataset and each data year was 0.25 µg/mL. Two twofolddilutions higher than the MIC50 (0.25 µg/mL) for the pooled dataset and each data year was 1.0 µg/mL.
Discussion: The epidemiological cut-off values chosen using methods 1 and 2 (≤1.0 µg/mL) were
identical for the pooled dataset and each data year, indicating the epidemiological cut-off value has not
changed from 2005-2012. The epidemiological cut-off value for N. gonorrhoeae azithromycin agar
dilution antimicrobial susceptibility testing established during this study can be used to help set clinical
breakpoints and identify isolates with reduced susceptibility to azithromycin.
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CHAPTER I
INTRODUCTION

Gonorrhea is the second most commonly reported notifiable disease in the United States.
It is estimated that there are over 820,000 new gonorrhea infections annually. Untreated
gonorrhea infections can cause serious and permanent health conditions in both men and women.
Gonorrhea can be treated with appropriate antimicrobial therapy, but increasing resistance to
commonly prescribed drugs may complicate our ability to treat infections in the near future.
Because Neisseria gonorrhoeae has developed resistance to many antibiotic therapies
used to treat gonococcal infections (penicillin, fluoroquinolones, oral cephalosporins),
antimicrobial susceptibility testing is becoming increasingly important to monitor resistance
trends and guide treatment. National, state, and private laboratories performing antimicrobial
susceptibility testing utilize the clinical breakpoints, or interpretive criteria, established by the
Clinical and Laboratory Standards Institute (CLSI) to differentiate between susceptible,
intermediate, and resistant bacterial isolates. Unfortunately, clinical breakpoints have not been
established for any N. gonorrheae azithromycin antimicrobial susceptibility testing method.
CDC currently recommends azithromycin, along with single-dose injectable cephalosporin
regimens, to treat uncomplicated gonococcal infections of the cervix, urethra, and rectum. As
such, interpretive criteria for N. gonorrhoeae azithromycin antimicrobial susceptibility testing
are needed to monitor resistance and guide treatment regimens.
CLSI’s methodology for establishing clinical breakpoints requires microbiological,
pharmokinetic, and clinical data. In the absence of established clinical breakpoints,
epidemiological cut-off values can be used to identify isolates without resistance mechanisms
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(wild type) from non-wild type isolates. This study will utilize existing Minimum Inhibitory
Concentration (MIC) data from CDC’s Gonococcal Isolate Surveillance Project (GISP) to
establish epidemiological cut-off values for azithromycin and N. gonorrhoeae as determined by
agar dilution.

Research Questions
1.

Do the MIC distributions for N. gonorrhoeae azithromycin agar dilution
antimicrobial susceptibility testing differ from 2005-2012?

2.

What is the epidemiological cut-off value for azithromycin for 2005-2012? Does
the epidemiological cut-off value differ from 2005-2012?
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CHAPTER II
REVIEW OF THE LITERATURE

2.1 Neisseria gonorrhoeae and Gonococcal Infection
Neisseria gonorrhoeae (gonococci) is the bacterium that causes gonorrhea and its associated
clinical syndromes. Gonorrhea is transmitted through vaginal, oral, or anal sex and can also be
transmitted from a mother to her unborn baby during childbirth. The World Health Organization
(WHO) estimated there were 106.1 million new cases of gonorrhea infections worldwide in
adults in 2008 (1). Gonorrhea is the second most commonly reported notifiable infection in the
United States. There were 321,849 cases reported in 2011 yielding a 4% increase in incidence
from 2010. Rates are highest in the Southern region of the United States, among women, and
persons 20-24 years of age (2).
The broad spectrum of clinical manifestations includes symptomatic and asymptomatic local
infection, complicated local infection, and systemic infection. While the majority of
uncomplicated gonococcal infections are asymptomatic, the most common presentation of
gonococcal infection in men is acute anterior urethritis accompanied by urethral discharge and/or
dysuria (painful urination). Untreated gonococcal infections typically resolve over a period of
several weeks and most patients become asymptomatic within six months. Complications, while
rare in developed countries, include epididymitis, lymphangitis, penile edema, acute or chronic
prostatitis, and periurethral abscesses (3).
The most common infection site in women is the endocervical canal, but urethral
colonization followed by infection of the periurethral (Skene’s) gland or Bartholin’s gland ducts
are also common in the absence of endocervical infection. Symptoms may include increased
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vaginal discharge, dysuria, intermenstrual uterine bleeding, and heavy or prolonged menstrual
periods (menorrhagia) (4). Pelvic inflammatory disease (PID), or the infection and inflammation
of the upper genital tract, is the most common complication of gonorrhea in women. PID is
accompanied by endometritis, tubo-ovarian abscess, or pelvic peritonitis and is also the most
important complication in terms of public health impact due to its associated long term sequelae
which include infertility, ectopic pregnancy, and chronic pelvic pain. It is estimated that between
10-20% of women with gonorrhea develop PID, and approximately eight percent of women in
the United States develop PID in their lifetime. Prevalence is much higher in developing
countries with rates as high as 32% (5-6).
Rectal infection is common in men who have sex with men (MSM), and up to 60% of
women with gonococcal cervicitis also have infection of the rectal mucosa. While infection of
the rectum in women is normally asymptomatic, rectal infection in men can be associated with
overt proctitis (7). Isolated pharyngeal infection has been documented in 3-7% of heterosexual
men, 10-20% of heterosexual women, and 10-25% of men who have sex with men. The majority
of infections are asymptomatic, but association with acute pharyngitis, tonsillitis, fever, or
cervical lymphadenopathy has been reported (4).
Gonococcal conjunctivitis and primary cutaneous gonorrhea, characterized by localized
ulcers of the genitals and skin lesions, are rare (4). Disseminated (or systemic) gonococcal
infection (DGI) is also rare and occurs in 0.2-1.9% of cases. DGI can occur in both males and
females, but incidence is thought to be higher in females. Symptoms include fever, joint pain,
skin rashes, and tenosynovitis. In very rare cases, disseminated gonococcal infection may
progress to endocarditis (8).
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N. gonorrhoeae and Chlamydia trachomatis co-infection is common. One cross sectional
study of new clients presenting to a hospital-based STD clinic in the United Kingdom found that
39% of 1,239 women and 24% of 1,141 heterosexual men with gonorrhea also had chlamydia. In
addition, more than half of the women and a third of the men 15-19 years of age were coinfected (9). Similarly, a study of adolescents entering selected United States detention centers
found that 54% of females and 51% of males with gonorrhea were also infected with chlamydia
(10). It is also widely understood that sexually transmitted infections (STIs) such as gonorrhea
increase the risk of acquiring and transmitting human immunodeficiency virus (HIV) by two to
five-fold and that aggressive STI prevention, screening, and treatment reduces the transmission
of HIV (11).
There are several populations that have a higher risk of acquiring STIs or experiencing
adverse health outcomes as a result of acquiring an STI. It is estimated that young people 15-24
years of age account for more than half of new STI cases in the United States. Risk factors such
as engagement in high-risk sexual behaviors and barriers to accessing quality STI prevention
services and care (concerns about confidentiality, lack of health insurance or ability to pay)
increases adolescents’ and young adults’ risk of acquiring gonorrhea (2). MSM represent an
estimated 2% of the United States male population, but they account for 59% of the people living
with HIV in the country. Because the risk factors that contribute to the transmission of STIs
(higher number of lifetime sex partners, higher partner acquisition rates, unprotected sex) also
increase the acquisition and transmission of HIV, MSM also bear a disproportionately high
burden of STIs (12, 13).
Gonorrhea affects approximately 13,200 pregnant women annually (14). Untreated infections
can lead to adverse pregnancy outcomes such as early onset of labor, spontaneous preterm birth,
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low birth weight, preterm rupture of membranes surrounding the uterus, miscarriage, and
stillbirth (15-17). Gonorrhea can also be transmitted from an infected mother to her baby during
delivery. Gonococcal ophthalmia neonatorum is the most common presentation of gonorrhea in
neonates, but scalp abscesses, wound infections, systemic disease (meningitis and sepsis), and
colonization of the oropharynx and gastric fluid can also occur (18). Genital infection in children
is rare and typically acquired through sexual abuse (19).

2.2 History of Treatment and Antibiotic Resistance Trends
Silver proteinate or Protargol was used to treat gonorrhea from the late 1890’s up to the
introduction of antibiotics in the mid 1930’s. The sulfonamides were the first effective
antimicrobials against gonorrhea, but resistance was widespread by the mid-1940’s. Penicillin
became the first line drug for treatment in 1943. Within 10-15 years treatment failures had been
reported, and higher doses were required for successful treatment. By 1989 penicillin was no
longer recommended for the treatment of gonorrhea. Streptomycin and chloramphenicol
(introduced in 1949), erythromycin (introduced in 1952), spectinomycin (introduced in 1961),
and tetracycline (introduced in 1962) were used when treatment with penicillin was
contraindicated, but strains resistant to these antibiotics emerged rapidly due to chromosomal
mutations and other gene acquisition events. By the late 1980’s most of these alternatives were
no longer recommended for treatment (20).
Fortunately third generation cephalosporins such as ceftriaxone and cefixime and
fluoroquinolones such as ciprofloxacin were highly effective against gonococci. By 1985
ceftriaxone became the recommended treatment for uncomplicated gonococcal infections, and in
1993, the oral fluoroquinolones (ciprofloxacin and ofloxacin) and cefixime were the
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recommended first line treatment (21). Resistance to fluorquinolones was recorded as early as
the mid-1990’s in South East Asia and in the United States as early as 1991 (Hawaii). Increasing
resistance to fluoroquinolones in the United States prompted the CDC to recommend the use of
cephalosporins over fluorquinoloes in Hawaii and California in 2002. This recommendation was
later expanded to include MSM in 2004, and fluoroquinolones were no longer recommended in
the United States by 2007 (22).
In recent years decreased susceptibility to third generation cephalosporins has been reported
from Asia and the Pacific region as well as Europe, Canada, and the United States. Cefixime
treatment failures were first reported in Japan in 2003 and have subsequently been reported in
the United Kingdom, Norway, Austria, and France. Widespread resistance to oral cephalosporins
prompted Japan to discontinue the use of cefixime for the treatment of gonorrhea in 2006.
In 2009, a strain with high-level ceftriaxone resistance was isolated in Kyoto, Japan from a
woman presenting with pharyngeal gonococcal infection. Subsequently, isolates with high-level
resistance to ceftriaxone have been identified in men with urogenital infections in Spain and
France (23). While ceftriaxone treatment failures have not yet been documented in the United
States, data from CDC’s GISP suggest the number of isolates with elevated ceftriaxone MIC’s
has markedly increased since 2006, particularly in the western region and among MSM (24).
CDC’s current treatment guidelines recommend combination therapy with 250 mg ceftriaxone
intramuscularly and either 1 g azithromycin orally as a single treatment or 100 mg doxycycline
twice daily for seven days (25).
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2.3 Azithromycin and the Treatment of Gonorrhea
Azithromycin is an azalide drug derived from the macrolide class of antibiotics. The
mechanism of action is inhibition of RNA-dependent peptide synthesis of bacteria by binding to
the 50s ribosomal subunit. Azithromycin became available for the treatment of gonorrhea in
1983, and it has proven effective as a single dose alternative to oral cephalosporins in
combination with ceftriaxone. It has also proven highly effective against pharyngeal infection,
genital co-infection with C. trachomatis, and penicillin-resistant strains (26). Azithromycin, in
combination with ceftriaxone, is one of the currently recommended first-line treatment regimens
for uncomplicated gonococcal infections in the United States.
Resistance to azithromycin was first reported in the United States in New Mexico in 1993.
The first isolate demonstrating high level resistance in the United States was identified in Hawaii
in 2011 (27); however, data from GISP suggests the proportion of isolates with high level
resistance to azithromycin remains low (28).

2.4 The Gonococcal Isolate Surveillance Project (GISP)
CDC established a national sentinel surveillance system known as the Gonococcal Isolate
Surveillance Project (GISP) in 1986 to 1) to monitor trends in antimicrobial resistance in N.
gonorrhoeae strains, 2) to characterize male patients with gonorrhea, especially those infected
with strains that are resistant to currently recommended therapies, and 3) to describe the diversity
of antimicrobial resistance in N. gonorrhoeae by phenotypically characterizing resistant isolates
via the agar dilution method. This method provides an MIC (vs. zone diameter), is wellcharacterized, and well-standardized, and as such, is considered the gold standard for N.
gonorrhoeae antimicrobial susceptibility testing. CDC prepares and distributes an annual report
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of the project’s findings, and data generated by GISP is used to inform selection of therapies for
gonococcal infection and to revise CDC’s STD Treatment Guidelines (29).

2.5 Clinical Breakpoints and Epidemiological Cut-off Values
Clinical breakpoints (CBPs) are values used by laboratories to classify MIC or zone
inhibition data generated from antimicrobial susceptibility assays into clinically relevant
categories i.e., susceptible, intermediate, or resistant to a particular antimicrobial agent (30).
Clinical breakpoints influence local, regional, and national treatment guidelines by categorizing
the susceptibility of previously tested isolates for a particular antimicrobial. In addition, clinical
breakpoints guide empiric treatment (31).
The Clinical and Laboratory Standards Institute (formerly known as the National Committee
for Clinical Laboratory Standards), established in 1968, is the international organization
responsible for developing the clinical laboratory testing standards used in the United States.
CLSI laboratory standards are established utilizing input from and consensus among
government, industry, and healthcare professionals. CLSI’s methodology for establishing clinical
breakpoints requires four main data types: (i) MIC (minimum inhibitory concentration)
distributions and epidemiological cut-off values (ECVs); (ii) phenotypic and genotypic in vitro
resistance markers; (iii) pharmokinetic data from animal models and human studies; and (iv)
clinical and bacteriological outcome data from clinical studies (32).
Currently there are no CLSI-established azithromycin clinical breakpoints for any N.
gonorrhoeae antimicrobial susceptibility testing method. In the absence of established clinical
breakpoints, epidemiological cut-off values can serve as a guide to differentiate wild-type strains
from strains with acquired resistance mechanisms. The construction of MIC distributions and the
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determination of epidemiological cut-off values is the first step in the development of clinical
breakpoints for azithromycin agar dilution antimicrobial susceptibility testing for N.
gonorrhoeae.
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CHAPTER III
METHODS

3.1 Definitions
MIC, or minimum inhibitory concentration, is defined as the lowest concentration of
antibiotic needed to inhibit visible growth of a microorganism in a laboratory. Wild-type, in the
context of this study, is defined as lacking acquired or mutational antibiotic resistance
mechanisms. ECV, or epidemiological cut-off value (synonymous with wild-type cut-off value),
is defined as the MIC value which best describes the end of the wild-type distribution. It is
expressed as ECV ≤ X µg/mL (33). Pooled dataset refers to data from 2005-2012. Raw MIC
data refers to untransformed MIC values. MIC50 is defined as the value at which 50% of the
isolates are inhibited. MIC99 is defined as the value at which 99% of the isolates are inhibited.

3.2 GISP Specimen Collection and Agar Dilution Susceptibility Testing
GISP sentinel STD clinics and regional laboratories are chosen for a 5-year term via an
application process administered by a CDC Funding Opportunity Announcement (FOA). STD
clinics and laboratories chosen as GISP sentinel sites and regional laboratories receive funding
from CDC to assist with GISP program requirements. Each month around 24 sentinel STD
clinics submit urethral isolates from the first 25-30 male patients presenting with urethral
gonococcal infection as well as clinical and demographic data to one of five regional
laboratories. The five current regional laboratories, located in Atlanta, Austin, Birmingham,
Cleveland, and Seattle, test the isolates for β-lactamase production via the Nitrocefin test and
antimicrobial susceptibility (minimum inhibitory concentrations, MIC’s) to penicillin G,
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tetracycline, spectinomycin, cefixime, ceftriaxone, ciprofloxacin, and azithromycin via the agar
dilution method. Results are reported to CDC on a monthly basis, and any isolate meeting Alert
Value MIC criteria (currently ≥ 2.0 µg/mL for azithromycin) undergoes confirmatory retesting
by the regional laboratory (34).

3.3 GISP Azithromycin MIC Data
Azithromycin was added to the GISP panel in 1992, and azithromycin MIC data is
available from 1992-2012. In 2005 there was a change in media used for agar dilution testing
among all GISP regional laboratories. This media change resulted in an observational shift of the
MIC distribution approximately equal to one twofold-dilution higher (35). Data from 1992-2004
were excluded from this analysis to ensure the consistency of laboratory methods for data
collection.

3.4 MIC Distributions
MIC distributions for azithromycin were constructed for 2005-2012 using Microsoft
Excel v.2010.

3.5 Statistical Analysis
All statistical analyses were performed using SAS/STAT® v.9.3 software (SAS Institute,
Cary, North Carolina, USA). The univariate procedure was used to fit pooled azithromycin MIC
values to normal and lognormal curves to test for normality. Data were then log2 transformed as
described previously, and the univariate procedure was again used to fit log2-transformed MIC
values to normal and lognormal curves to test for normality. Levene’s test (glm procedure) and
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one-way analysis of variance (ANOVA) were used with raw MIC data to test for homogeneity of
variances and differences in mean azithromycin MIC from 2005-2012 (36). The Kruskal- Wallis
test was conducted on raw MIC data using the npar1way procedure to test for underlying
differences in the azithromycin MIC distributions from 2005-2012 (α = 0.05). The WilcoxonMann-Whitney test was then used to test for differences in the azithromycin MIC distribution
from year to year (i.e., 2005-2006, 2006-2007, etc.) using raw MIC data (α = 0.05). The
univariate procedure was then used to calculate the median, mode, MIC50, MIC90, and MIC99 for
each data year and the pooled dataset.

3.6 Calculation of Epidemiological Cut-off Values
Two methods were used to calculate epidemiological cut-off values. Method 1, often
called the “eyeball method,” considers the wild-type MIC distribution, the modal MIC for the
distribution, and the inherent variability of the test (±1 twofold-dilution) to determine the
epidemiological cut-off value. In addition, the epidemiological cut-off value should encompass
at least 95% of the isolates in the wild-type distribution (37). The mode and modal MIC ±1
twofold-dilution were calculated for each data year. MIC values that 1) were larger than the
modal MIC +1 twofold-dilution and 2) included at least 95% of isolates in the wild-type
distribution were used to identify epidemiological cut-off values via visual inspection of each
MIC distribution. Method 2 defines the epidemiological cut-off value as two twofold-dilutions
higher than the MIC50 (38).
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CHAPTER IV
RESULTS

4.1 MIC Distributions and Descriptive Statistics
Azithromycin MIC distributions for data years 2005-2006 can be found below in Figures
1-8.
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Figure 1. MIC distribution for azithromycin, 2005.
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Figure 2. MIC distribution for azithromycin, 2006.

Azithromycin MIC Distribution, 2007
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Figure 3. MIC distribution for azithromycin, 2007.
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Figure 4. MIC distribution for azithromycin, 2008.

Azithromycin MIC Distribution, 2009
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Figure 5. MIC distribution for azithromycin, 2009.
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Figure 6. MIC distribution for azithromycin, 2010.

Azithromycin MIC Distribution, 2011
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Figure 7. MIC distribution for azithromycin, 2011.
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Figure 8. MIC distribution for azithromycin, 2012.

There were 6,199 observations in 2005, 6,089 observations in 2006, 6,009 observations
in 2007, 5,723 observations in 2008, 5,630 observations in 2009, 5,693 observations in 2010,
5,467 observations in 2011, and 5,495 observations in 2012 for a total of 46,305 observations
from 2005-2012. The mean MIC values for each data year, 2005-2012, were 0.281 µg/mL, 0.283
µg/mL, 0.343 µg/mL, 0.337 µg/mL, 0.290 µg/mL, 0.303 µg/mL, 0.264 µg/mL , and 0.311
µg/mL, respectively. The mean MIC value for the pooled dataset was 0.301 µg/mL. The median
azithromycin MIC (or MIC50) for each data year and the pooled dataset was 0.250 µg/mL.
Descriptive statistics are summarized in Table 1.
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Table 1. Descriptive statistics, GISP azithromycin MIC data, 20052012.

2005
2006
2007
2008
2009
2010
2011
2012
20052012

N

Mean
(µg/mL)

Median
(µg/mL)

Mode
(µg/mL)

Range
(µg/mL)

6,199
6,089
6,009
5,723
5,630
5,693
5,467
5,495

0.281
0.283
0.343
0.337
0.290
0.303
0.265
0.311

0.250
0.250
0.250
0.250
0.250
0.250
0.250
0.250

0.250
0.250
0.250
0.250
0.250
0.250
0.250
0.250

15.99
15.99
15.99
15.97
15.99
15.99
15.99
255.99

46,305

0.301

0.250

0.250

255.99

4.2 Goodness-of-fit Tests for Normality and Equal Variances
There is statistically significant evidence that the pooled dataset is not normally
distributed. The azithromycin MIC distribution for 2005-2012 (pooled dataset) fit poorly to
normal and lognormal distributions as indicated by the Anderson-Darling goodness-of-fit tests
(Table 2). The p values for both normal and lognormal distributions were <0.005 (α = 0.05).
Log2 transformation of MIC values did not improve fit for either distribution. Levene’s test for
homogeneity of variance indicated equal variances among the eight data years (2005-2012) with
an F statistic of 1.06 and a p value of 0.3883 (α =0.05).

Table 2. Anderson-Darling goodness-of-fit tests, GISP azithromycin MIC data, 2005-2012.
Normal Distribution
Lognormal Distribution

A2
12361.38
1515.70
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p (α =0.05)
<0.005
<0.005

4.3 Tests for Differences in Azithromycin MIC Distributions
ANOVA indicated the mean azithromycin MIC differed significantly among the data
years, 2005-2012 (F statistic = 2.62 and p = 0.0104; α = 0.05). While the median MIC for the
pooled dataset and each data year were equivalent at 0.25 µg/mL, the Kruskal-Wallis test also
indicated a statistically significant difference in the underlying azithromycin MIC distributions
for the pooled dataset (χ2 = 849.87; p = <0.0001). There were no statistically significant
differences in the azithromycin MIC distributions from 2007-2008 (Z = 0.44; p =0.6585), 20102011 (Z = -1.50; p = 0.1330), and 2011-2012 (Z = -1.89; p = 0.0593). Table 3 shows the results
of the Wilcoxon-Mann-Whitney two-sample comparisons.

Table 3. Comparison of azithromycin MIC distributions using the Wilcoxon-MannWhitney two-sample test, 2005-2012.
2005-2006
2006-2007
2007-2008
2008-2009
2009-2010
2010-2011
2011-2012

Z

p (α =0.05)

6.35
10.91
0.44*
-13.26
3.55
-1.50*
-1.89*

<0.0001
<0.0001
0.6585*
<0.0001
0.0004
0.1330*
0.0593*

*No statistically significant difference in azithromycin MIC distributions.

4.4 Epidemiological Cut-off Values (ECVs)
As referenced in Table 1, the modal MIC for the pooled dataset and each azithromycin
MIC distribution (2005-2012) was 0.25 µg/mL. The modal MIC ±1 twofold-dilution for the
pooled dataset and each data year ranged from 0.125 to 0.5 µg/mL. Taking into consideration the
wild-type MIC distributions (Figures 1-8) and the inherent variability of the test, the
epidemiological cut-off value chosen for the pooled dataset and each data year using Method 1
20

was ≤1.0 µg/mL (Table 4). This cut-off encompassed 99% of the MICs in the pooled dataset and
each data year.
The MIC50 for the pooled dataset and each data year was 0.25 µg/mL. Two twofolddilutions higher than the MIC50 (0.25 µg/mL) for the pooled dataset and each data year was 1.0
µg/mL. The epidemiological cut-off value chosen for the pooled dataset and each data year using
Method 2 was ≤1.0 µg/mL (Table 4). Again, the chosen epidemiological cut-off value
encompassed 99% of MICs in the pooled dataset and each data year.
The epidemiological cut-off values were identical for Methods 1 and 2 for each data year
and the pooled dataset (Figure 9).

Table 4. ECVs obtained from GISP Azithromycin MIC† data, 2005-2012
Year

N

Mode

MIC50

MIC99

Method 1
ECV*

Method 2
ECV**

2005
2006
2007
2008
2009
2010
2011
2012
2005-2012

6,199
6,089
6,009
5,723
5,630
5,693
5,467
5,495
46,305

0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25

0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25
0.25

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

†MIC (µg/mL)
*ECV considers the wild-type MIC distribution, the modal MIC, the inherent variability of the test (±1 twofold
dilution), and should encompass at least 95% of isolates in the wild-type distribution.
**ECV = two twofold dilution steps higher than MIC50
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Azithromycin MIC Distribution, 2005-2012
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Figure 9. Epidemiological cut-off value for azithromycin, 2005-2012.
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CHAPTER V
DISCUSSION

5.1 Implications

This study aimed to 1) determine if azithromycin MIC distributions for N. gonorrhoeae
have changed from 2005-2012 and 2) to calculate epidemiological cut-off values for 2005-2012
GISP azithromycin agar dilution MIC data and determine whether or not the epidemiological
cut-off values differ during this time period. A statistically significant difference in the
underlying MIC distributions was observed between the eight data years; however, no
statistically significant differences were found in MIC distributions from 2007-2008, 2010-2011,
and 2011-2012. Interestingly, while the Wilcoxon-Mann-Whitney test demonstrated statistically
significant differences in the MIC distributions from 2005-2006, 2006-2007, 2008-2009, and
2009-2010, the median azithromycin MIC for the pooled data set and each data year were
identical at 0.25µg/mL. This is most likely due to the large sample sizes as the difference in
ranks were large enough to be significant despite equal medians.
The epidemiological cut-off value selected for each data year and the pooled dataset was
≤1.0 µg/mL indicating the epidemiological cut-off value did not change from 2005-2012. While
the Kruskal-Wallis test indicated a statistically significant difference in the underlying MIC
distributions from 2005-2012, the lack of change in epidemiological cut-off value indicates the
wild-type distribution has not shifted during this time period. In addition, the epidemiological
cut-off values chosen using Method 1 and Method 2 were identical, suggesting that, for this
dataset, both methods were comparable. Using this epidemiological cut-off value, isolates with
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an MIC less than or equal to 1.0 µg/mL may be considered wild-type, whereas isolates with an
MIC of 2.0 µg/mL or higher may have decreased susceptibility to azithromycin.

5.2 Future Considerations
More robust statistical procedures for the calculation of epidemiological cut-off values
have been described previously for different bacteria-antimicrobial combinations, but
comparison studies of these methods to Methods 1 and 2 used in this study show comparable
results, usually within one twofold-dilution (39-42). As a result, only methods 1 and 2 were used
for this analysis. Application of these statistical methods may be useful in the future for the
establishment of clinical breakpoints for azithromycin agar dilution antimicrobial susceptibility
testing for N. gonorrhoeae. In addition, genotypic markers of resistance were not included in this
study. Examination of MIC distributions in tandem with molecular markers of resistance can
provide a better understanding of the clinical importance of isolates with reduced susceptibility
to azithromycin by confirming if such isolates harbor resistance mechanisms. Lastly, agar
dilution antimicrobial susceptibility testing capacity for N. gonorrhoeae is limited in the United
States. Similar studies should be conducted utilizing zone diameter and MIC data collected via
E-tests to establish epidemiological cut-off values for azithromycin disk diffusion and E-test
procedures.
One gram azithromycin given orally in combination with 250mg ceftriaxone given as a
single intramuscular dose is one of two currently recommend treatment regimens for
uncomplicated gonococcal infections of the cervix, urethra, and rectum. As such, clinicians
require azithromycin antimicrobial susceptibility data to monitor resistance. Clinical laboratories
may be reluctant to perform azithromycin antimicrobial susceptibility testing for N. gonorrhoeae
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because results are difficult to interpret without established clinical breakpoints. The lack of
established breakpoints for N. gonorrhoeae azithromycin antimicrobial susceptibility testing
hinders surveillance and hampers the management of patients who fail treatment. While
epidemiological cut-off values cannot replace clinical breakpoints, they are the first crucial step
in the establishment of clinical breakpoints by CLSI and other standard-setting institutes. The
epidemiological cut-off value for azithromycin and N. gonorrhoeae agar dilution antimicrobial
susceptibility testing established here can be used to help set clinical breakpoints and identify
isolates with reduced susceptibility to azithromycin.
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